Current Document Type: HighlightsVideoPage Relapsed Refractory Multiple Myeloma Clinical Outcomes After Treatment With Bispecific Antibodies - JADPRO

Watch More Highlights

Kathryn Tyler Maples, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses data of key importance for advanced practitioners on patients with multiple myeloma who are heavily pretreated and predominantly triple-class refractory, and who relapse after receiving bispecific antibodies (BiAbs). These patients may still have good outcomes when sequentially treated with other immunologic or T-cell–directed therapeutics such as BiAbs and CAR-T cells (Abstract 821).

Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.